INMD News and Press, InMode Ltd. From 01/30/24

2024-01-30 18:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-21 03:49:13 ET Summary InMode's stock valuation has fluctuated over time, with high multiples in 2021 due to impressive growth. The company's growth has since slowed down as it has matured. However, current multiples seem perhaps too punishing, with short-term possible...

2024-01-19 20:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-16 07:29:15 ET More on InMode InMode: Despite Attractive Valuation, I Believe It's Premature To Dive In - Here's Why InMode Is Inherently Undervalued - Bullish Support Observed InMode: A Deep Analysis Into Its Mixed Picture Inmode stock slides after m...

InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024, Expects Q4 Revenue Between $126.0M-$126.5M InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024, Expects Q4 Reven...

2024-01-15 15:49:19 ET More on Align Technology, DexCom, etc. Intuitive Surgical: Strong Pre-Announced Q4 - Time To Harvest The Gain, Initiate With 'Sell' Intuitive Surgical, Inc. (ISRG) JPMorgan Healthcare Conference Call Transcript Intuitive Surgical: Sustained Gro...

2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...

2024-01-03 03:16:23 ET Summary InMode has a depressed valuation with a forward P/E of 8.70 in 2024. The company is facing challenges with falling revenue and EBITDA, despite being highly profitable. The weakening of Covid pent-up demand adds an interesting layer to the investm...

2024-01-02 10:00:00 ET Summary INMD continues to report robust consumable sales, with the downgraded FY2023 top-line guidance only attributed to the elevated interest rate environment. With the Fed already signaling a potential pivot in Q1'24, investors only need to be patient for...

2023-12-14 16:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...